Active 0 6 0 6 O
, 6 7 6 7 O
known 8 13 8 13 O
or 14 16 14 16 O
suspected 17 26 17 26 O
autoimmune 27 37 27 37 B-chronic_disease
disease 38 45 38 45 I-chronic_disease
or 46 48 46 48 O
severe 49 55 49 55 O
hypersensitivity 56 72 56 72 O
reactions 73 82 73 82 O
to 83 85 83 85 O
other 86 91 86 91 O
monoclonal 92 102 92 102 B-allergy_name
antibodies 103 113 103 113 I-allergy_name

Brain 0 5 114 119 B-cancer
metastases 6 16 120 130 I-cancer
that 17 21 131 135 O
have 22 26 136 140 O
not 27 30 141 144 O
been 31 35 145 149 O
adequately 36 46 150 160 O
treated 47 54 161 168 O

Diagnosis 0 9 169 178 O
of 10 12 179 181 O
locally 13 20 182 189 O
advanced 21 29 190 198 O
or 30 32 199 201 O
metastatic 33 43 202 212 O
cancer 44 50 213 219 B-cancer
that 51 55 220 224 O
has 56 59 225 228 O
progressed 60 70 229 239 O
despite 71 78 240 247 O
standard 79 87 248 256 B-treatment
therapy 88 95 257 264 I-treatment
or 96 98 265 267 O
for 99 102 268 271 O
which 103 108 272 277 O
no 109 111 278 280 O
effective 112 121 281 290 O
standard 122 130 291 299 O
therapy 131 138 300 307 O
exists 139 145 308 314 O
and 146 149 315 318 O
histological 150 162 319 331 O
confirmation 163 175 332 344 O

Impaired 0 8 345 353 B-chronic_disease
cardiac 9 16 354 361 I-chronic_disease
function 17 25 362 370 I-chronic_disease

Impairment 0 10 371 381 B-chronic_disease
of 11 13 382 384 I-chronic_disease
gastrointestinal 14 30 385 401 I-chronic_disease
function 31 39 402 410 I-chronic_disease
or 40 42 411 413 O
gastrointestinal 43 59 414 430 B-chronic_disease
disease 60 67 431 438 I-chronic_disease
that 68 72 439 443 O
may 73 76 444 447 O
significantly 77 90 448 461 O
alter 91 96 462 467 O
the 97 100 468 471 O
absorption 101 111 472 482 O
of 112 114 483 485 O
oral 115 119 486 490 B-treatment
LGK974 120 126 491 497 I-treatment
( 127 128 498 499 O
e.g. 128 132 499 503 O
, 132 133 503 504 O
ulcerative 134 144 505 515 O
diseases 145 153 516 524 O
, 153 154 524 525 O
uncontrolled 155 167 526 538 O
nausea 168 174 539 545 B-chronic_disease
, 174 175 545 546 O
vomiting 176 184 547 555 B-chronic_disease
, 184 185 555 556 O
diarrhea 186 194 557 565 B-chronic_disease
, 194 195 565 566 O
malabsorption 196 209 567 580 B-chronic_disease
syndrome 210 218 581 589 I-chronic_disease
, 218 219 589 590 O
small 220 225 591 596 B-treatment
bowel 226 231 597 602 I-treatment
resection 232 241 603 612 I-treatment
) 241 242 612 613 O

LGK974 0 6 614 620 B-treatment
with 7 11 621 625 I-treatment
PDR001 12 18 626 632 I-treatment
: 18 19 632 633 O
Dose 20 24 634 638 O
escalation 25 35 639 649 O
: 35 36 649 650 O
patients 37 45 651 659 O
with 46 50 660 664 O
the 51 54 665 668 O
following 55 64 669 678 O
cancers 65 72 679 686 B-cancer
that 73 77 687 691 O
were 78 82 692 696 O
previously 83 93 697 707 B-treatment
treated 94 101 708 715 I-treatment
with 102 106 716 720 I-treatment
anti 107 111 721 725 I-treatment
- 111 112 725 726 I-treatment
PD-1 112 116 726 730 I-treatment
therapy 117 124 731 738 I-treatment
and 125 128 739 742 O
whose 129 134 743 748 O
best 135 139 749 753 O
response 140 148 754 762 O
on 149 151 763 765 O
that 152 156 766 770 O
therapy 157 164 771 778 O
was 165 168 779 782 O
progressive 169 180 783 794 B-chronic_disease
disease 181 188 795 802 I-chronic_disease
( 189 190 803 804 O
i.e. 190 194 804 808 O
primary 195 202 809 816 O
refractory 203 213 817 827 O
): 213 215 827 829 O
melanoma 216 224 830 838 B-cancer
, 224 225 838 839 O
lung 226 230 840 844 B-cancer
SCC 231 234 845 848 I-cancer
, 234 235 848 849 O
HNSCC 236 241 850 855 B-cancer
. 241 242 855 856 O
Patients 243 251 857 865 O
with 252 256 866 870 O
esophageal 257 267 871 881 B-cancer
SCC 268 271 882 885 I-cancer
, 271 272 885 886 O
cervical 273 281 887 895 B-cancer
SCC 282 285 896 899 I-cancer
or 286 288 900 902 O
TNBC 289 293 903 907 B-cancer
who 294 297 908 911 O
are 298 301 912 915 O
either 302 308 916 922 O
na√Øve 309 314 923 928 O
or 315 317 929 931 O
primary 318 325 932 939 O
refractory 326 336 940 950 O
to 337 339 951 953 O
prior 340 345 954 959 B-treatment
anti 346 350 960 964 I-treatment
- 350 351 964 965 I-treatment
PD-1 351 355 965 969 I-treatment
therapy 356 363 970 977 I-treatment

LGK974 0 6 978 984 B-treatment
with 7 11 985 989 I-treatment
PDR001 12 18 990 996 I-treatment
: 18 19 996 997 O
Dose 20 24 998 1002 O
expansion 25 34 1003 1012 O
: 34 35 1012 1013 O
patients 36 44 1014 1022 O
with 45 49 1023 1027 O
pancreatic 50 60 1028 1038 B-cancer
cancer 61 67 1039 1045 I-cancer
, 67 68 1045 1046 O
or 69 71 1047 1049 O
TNBC 72 76 1050 1054 B-cancer
, 76 77 1054 1055 O
or 78 80 1056 1058 O
melanoma 81 89 1059 1067 B-cancer
, 89 90 1067 1068 O
or 91 93 1069 1071 O
head 94 98 1072 1076 B-cancer
and 99 102 1077 1080 I-cancer
neck 103 107 1081 1085 I-cancer
cancer 108 114 1086 1092 I-cancer

Malignant 0 9 1093 1102 B-cancer
disease 10 17 1103 1110 O
other 18 23 1111 1116 O
than 24 28 1117 1121 O
that 29 33 1122 1126 O
being 34 39 1127 1132 O
treated 40 47 1133 1140 O
in 48 50 1141 1143 O
this 51 55 1144 1148 O
study 56 61 1149 1154 O

Osteoporosis 0 12 1155 1167 B-chronic_disease
, 12 13 1167 1168 O
severe 14 20 1169 1175 O
or 21 23 1176 1178 O
untreated 24 33 1179 1188 O
osteopenia 34 44 1189 1199 B-chronic_disease

Pathologic 0 10 1200 1210 B-chronic_disease
bone 11 15 1211 1215 I-chronic_disease
fracture 16 24 1216 1224 I-chronic_disease

Single 0 6 1225 1231 O
Agent 7 12 1232 1237 O
Dose 13 17 1238 1242 O
escalation 18 28 1243 1253 O
part 29 33 1254 1258 O
: 33 34 1258 1259 O
documented 34 44 1259 1269 O
B 45 46 1270 1271 O
- 46 47 1271 1272 O
RAF 47 50 1272 1275 O
mutant 51 57 1276 1282 O
colorectal 58 68 1283 1293 B-cancer
cancer 69 75 1294 1300 I-cancer
or 76 78 1301 1303 O
pancreatic 79 89 1304 1314 B-cancer
adenocarcinoma 90 104 1315 1329 I-cancer

Single 0 6 1330 1336 O
Agent 7 12 1337 1342 O
Dose 13 17 1343 1347 O
expansion 18 27 1348 1357 O
part 28 32 1358 1362 O
: 32 33 1362 1363 O
documented 34 44 1364 1374 O
B 45 46 1375 1376 O
- 46 47 1376 1377 O
RAF 47 50 1377 1380 O
mutant 51 57 1381 1387 O
colorectal 58 68 1388 1398 B-cancer
cancer 69 75 1399 1405 I-cancer
with 76 80 1406 1410 O
documented 81 91 1411 1421 O
RNF43 92 97 1422 1427 O
mutation 98 106 1428 1436 O
and/or 107 113 1437 1443 O
RSPO 114 118 1444 1448 O
fusion 119 125 1449 1455 O
or 126 128 1456 1458 O
pancreatic 129 139 1459 1469 B-cancer
adenocarcinoma 140 154 1470 1484 I-cancer
with 155 159 1485 1489 O
documented 160 170 1490 1500 O
RNF43 171 176 1501 1506 O
mutation 177 185 1507 1515 O

patients 0 8 1516 1524 O
with 9 13 1525 1529 O
tumors 14 20 1530 1536 B-cancer
of 21 23 1537 1539 O
any 24 27 1540 1543 O
histological 28 40 1544 1556 O
origin 41 47 1557 1563 O
with 48 52 1564 1568 O
documented 53 63 1569 1579 O
genetic 64 71 1580 1587 O
alterations 72 83 1588 1599 O
upstream 84 92 1600 1608 O
in 93 95 1609 1611 O
the 96 99 1612 1615 O
Wnt 100 103 1616 1619 O
signaling 104 113 1620 1629 O
pathway 114 121 1630 1637 O
( 122 123 1638 1639 O
e.g. 123 127 1639 1643 O
RNF43 128 133 1644 1649 O
or 134 136 1650 1652 O
RSPO 137 141 1653 1657 O
fusion 142 148 1658 1664 O
) 148 149 1664 1665 O
are 150 153 1666 1669 O
eligible 154 162 1670 1678 O
with 163 167 1679 1683 O
prior 168 173 1684 1689 O
agreement 174 183 1690 1699 O
with 184 188 1700 1704 O
Novartis 189 197 1705 1713 O

tumors 0 6 1714 1720 B-cancer
of 7 9 1721 1723 O
any 10 13 1724 1727 O
histological 14 26 1728 1740 O
origin 27 33 1741 1747 O
with 34 38 1748 1752 O
documented 39 49 1753 1763 O
genetic 50 57 1764 1771 O
alterations 58 69 1772 1783 O
upstream 70 78 1784 1792 O
in 79 81 1793 1795 O
the 82 85 1796 1799 O
Wnt 86 89 1800 1803 O
signaling 90 99 1804 1813 O
pathway 100 107 1814 1821 O
are 108 111 1822 1825 O
eligible 112 120 1826 1834 O
with 121 125 1835 1839 O
prior 126 131 1840 1845 O
agreement 132 141 1846 1855 O
with 142 146 1856 1860 O
Novartis 147 155 1861 1869 O

